Loading…
The haemodynamic effects of ketanserin versus dihydralazine in severe early‐onset hypertension in pregnancy
Objective To compare the haemodynamic efficacy of ketanserin (a selective serotonin2‐receptor blocker) with dihydralazine in the management of severe early‐onset hypertension in pregnancy. Design Subgroup analysis within a randomised prospective multicentre trial to compare haemodynamic effects as m...
Saved in:
Published in: | BJOG : an international journal of obstetrics and gynaecology 1998-07, Vol.105 (7), p.723-731 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Objective
To compare the haemodynamic efficacy of ketanserin (a selective serotonin2‐receptor blocker) with dihydralazine in the management of severe early‐onset hypertension in pregnancy.
Design
Subgroup analysis within a randomised prospective multicentre trial to compare haemodynamic effects as measured by pulmonary artery catherization.
Setting
Departments of Obstetrics and Gynaecology and Intensive Care Medicine, Free University Hospital, Amsterdam and Sophia Hospital, Zwolle.
Participants
Thirty‐one women with a diastolic blood pressure > 110 mmHg and a gestational age between 26 and 32 weeks.
Results
The antihypertensive efficacy of both drugs was comparable. Dihydralazine significantly increased cardiac output (P < 0.01), while ketanserin induced only minor changes in cardiac output. Systemic vascular resistance decreased in both groups, but the decrease was significantly more pronounced with dihydralazine compared with ketanserin. Ketanserin induced a significant but not clinically relevant increase in heart rate (P < 0.01, while dihydralazine caused marked tachycardia (P < 0.005). Left ventricular stroke work index was reduced to similar values in both groups.
Conclusions
The antihypertensive profile of ketanserin is characterised by an early and gradual reduction of blood pressure in combination with a moderate decrease in systemic vascular resistance and no significant change in cardiac output. Dihydralazine causes market tachycardia resulting in a considerable increase in cardiac output. |
---|---|
ISSN: | 1470-0328 0306-5456 1471-0528 1365-215X |
DOI: | 10.1111/j.1471-0528.1998.tb10202.x |